Worthington Steel Stock Price, News & Analysis

Vicarious Surgical Inc. (NYSE: RBOT) will release its fourth quarter 2021 financial results on March 3, 2022, after market close. A conference call, starting at 4:30 p.m. ET, will follow to discuss the results. Investors can participate by calling 1 (646) 904 5544 domestically or +1 (929) 526 1599 internationally. Vicarious Surgical, founded in 2014, focuses on enhancing surgical efficiency and reducing healthcare costs using proprietary robotic technology.

Energy Vault (NRGV, NRGV WS) commenced trading on February 14, 2022, following its business combination with Novus Capital Corporation II. The transaction secured approximately $235 million in gross proceeds, supplementing a $107 million Series C funding and a $50 million licensing fee from Atlas Renewable. This capital will support Energy Vault's growth strategy in sustainable, grid-scale energy storage technologies aimed at decarbonization. CEO Robert Piconi emphasized the strategic partnerships enhancing shareholder value.

Novus Capital Corporation II (NYSE: NXU, NXUU, WS) has received stockholder approval for its business combination with Energy Vault, Inc. at a special meeting held on February 10, 2022. The transaction is expected to close on February 11, 2022, and the new entity will be named Energy Vault Holdings, Inc., with trading commencing on February 14, 2022 under ticker symbols 'NRGV' and 'NRGV WS'. Energy Vault specializes in sustainable energy storage technologies aimed at reducing energy costs for utilities and large industrial users.

Energy Vault will host a fireside chat with IPO Edge on February 8, 2022, at 2pm ET to discuss its business combination with Novus Capital Corporation II (NYSE: NXU). The chat will cover Energy Vault's gravity-based energy storage technology and recent partnerships with DG Fuels LLC, BHP, and others. The Special Meeting to approve the merger is set for February 10, 2022, at 10:00 a.m. ET. If approved, trading under new ticker symbols 'NRGV' and 'NRGV WS' will commence shortly thereafter.

Novus Capital Corporation II (NYSE: NXU, NXU WS, NXU.U) urges stockholders to vote for the proposed business combination with Energy Vault, Inc. The Special Meeting is scheduled for February 10, 2022, at 10:00 a.m. ET, where stockholders can approve the merger. Should the deal go through, trading of the combined entity's shares will commence under the new ticker symbols 'NRGV' and 'NRGV WS' on the NYSE. Stockholders are encouraged to submit their proxy votes by 11:59 p.m. ET on February 9, 2022.

Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) will engage in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 4:00 p.m. Eastern Time. The company focuses on enhancing surgical procedures through next-generation robotic technology, which has been recognized by the FDA with a Breakthrough Device Designation. Founded in 2014, Vicarious Surgical aims to improve patient outcomes while reducing healthcare costs. The event is accessible via BTIG representatives.

Alvotech has entered into an exclusive global licensing agreement with BiosanaPharma to co-develop AVT23, a proposed biosimilar to Xolair, which had global sales of $3.3 billion in 2020. AVT23 will leverage BiosanaPharma's proprietary 3C process technology for low-cost manufacturing. Under the agreement, Alvotech gains exclusive global rights, while BiosanaPharma receives an upfront payment and tiered royalties. AVT23 is currently in late-stage development, with prior studies showing favorable bioavailability and safety compared to Xolair.

Novus Capital Corporation II (NYSE:NXU, NXU WS) announced the SEC has declared effective its Registration Statement on Form S-4 regarding a merger with Energy Vault, Inc., a sustainable energy storage solutions provider. A Special Meeting for Novus stockholders is set for February 10, 2022, to approve the Business Combination, with a deadline for proxy submissions by February 9, 2022. If approved, trading under the new ticker symbol 'NRGV' is anticipated to begin shortly thereafter. Energy Vault's solutions aim to reduce costs for utilities and enhance energy supply reliability.

Health Canada has approved the marketing of SIMLANDI (AVT02), a biosimilar to Humira, developed by Alvotech in collaboration with JAMP Pharma. This approval permits the launch of high-concentration presentations (40 mg/0.4 mL and 80 mg/0.8 mL) in Canada, which previously lacked such options. With Humira's global sales exceeding $20 billion and $700 million in Canada, the launch positions SIMLANDI to capture significant market share. JAMP Pharma aims to provide a lower-cost alternative, ultimately offering patients a citrate-free option and fewer injections.